Midtown-based drug discovery company Schrodinger has entered a deal to advance multiple projects with pharmaceutical giant ...
Schrödinger Inc.’s stock soared 9% early Tuesday, after the company said it has entered a multi-year collaboration agreement ...
Novartis (NVS) has been beaten down lately with too much selling pressure. While the stock has lost 9.7% over the past four ...
Hidradenitis suppurativa (HS) is a relatively common skin disease, affecting as many as one percent of people worldwide. But ...
In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Schrodinger (SDGR – Research Report), with a ...
Novartis AG's revenue and core EPS topped analysts' expectations in Q3. Click here to read more on the analysis of NVS stock ...
Schrödinger shares rise as they announce a research partnership and licensing agreement with Novartis AG. Schrödinger will ...
Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...
Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...
Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales ...
Schrodinger (SDGR) today announced a research collaboration and license agreement with Novartis (NVS) to advance multiple development ...
The majority of U.S. stock indices ended lower on Nov. 12, as rising U.S. treasury yields posed a headwind to the equities’ ...